Guidelines for using glucagon

It only takes one severe hypoglycemic event
to devastate a patient
That's why The ADA Standards of Care
recommend glucagon for all patients
at risk of moderate or severe hypoglycemia.
American Diabetes
Glucagon should be prescribed for all individuals at increased risk of level 2 or 3 hypoglycemia so that it is available should it be needed. Glucagon administration is not limited to health care professionals.1
Despite ADA recommendations,
glucagon is still highly underutilized

9 out of 10 patients*
experienced BG <54 mg/dL over
the last 12 months.2

Even with this high burden, utilization
of glucagon emergency kits is low.
Only one-fifth use GEKs.3

Patients experience a range of hypoglycemia1,4,5
Normal Range 80-130 mg/dL
Mild hypoglycemia (level 1) <70 mg/dL
Moderate hypoglycemia (level 2) <54 mg/dL
Severe hypoglycemia (level 3)
The ADA recommends glucagon be
used in people unable or unwilling to eat.1
Gvoke® should be used when any of the following are true:5

Patient has tried correcting hypoglycemia sugar (or drinks that are high in sugar) and has not improved

Patient is unable to safely swallow sugar or sugar-sweetened products to correct hypoglycemia

Patient feels like they might pass out

Patient experiences loss of consciousness or a seizure

Gvoke can be used even before
the patient passes out5
Patients can even give themselves Gvoke in certain situations3

Those around patients should be shown how to use Gvoke before an emergency happens.
They may need to administer it if the patient has severe hypoglycemia.

References: 1. American Diabetes Association. Glycemic targets: Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(suppl 1):S73-S84. 2. Data on file. 3. Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther. 2019;21(9):522-530. 4. National Institute of Diabetes and Digestive and Kidney Diseases. Hypoglycemia. Published July 2021. Accessed October 7, 2021. 5. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2021.